CZO: Double-digit revenue YoY growth in 2020 vs 2019CZO's double-digit revenue YoY growth in 2020 is a sure thing and those who allege whatever else need to learn how to read an annual report. They also have to keep in mind that they do not talk to idiots when they post their clueless comments here.
CZO reported revenue YoY growth in 2019 versus 2018, facts below:
https://www.globenewswire.com/news-release/2020/04/16/2017361/0/en/Ceapro-Inc-Reports-Fourth-Quarter-and-Full-Year-2019-Results-and-Highlights.html
CZO also reported revenue YoY growth in the first nine months of 2020 compared with the first nine months of 2019, facts below:
https://www.globenewswire.com/news-release/2020/11/27/2135353/0/en/Ceapro-Inc-Reports-2020-Third-Quarter-and-Nine-Month-Financial-Results-and-Operational-Highlights.html
On top of this, CZO stated recently in its Q3 report that:
“Looking ahead, while taking into account the ongoing potential economic impact related to COVID-19 and evolving consumption trends, we believe Ceapro is well-positioned to once again deliver a double-digit growth in sales well in line with the positive trend achieved over the last years. With a strong balance sheet, a group of dedicated people, and a solid base business, coupled with the innovative technologies and products that we have developed to enable us to expand, Ceapro is poised to emerge as a successful life science company,” concluded Mr. Gagnon.
These are the facts from the company's reports although they do not help some investors' agenda.